The GERAS study: A prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries - Study design and baseline findings

Journal of Alzheimer's Disease

Volumn 36, Issue 2, 2013, Pages 385-399

  Wimo, Anders ^a   Reed, Catherine C ^b   Dodel, Richard ^c   Belger, Mark ^b   Jones, Roy W ^d   Happich, Michael ^b   Argimon, Josep M ^e   Bruno, Giuseppe ^f   Novick, Diego ^b   Vellas, Bruno ^g   Haro, Josep Maria ^h  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ELI LILLY AND COMPANY   (United States)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d ROYAL UNITED HOSPITAL   (United Kingdom)

^e Divisió d'avaluació   (Spain)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g Faculté de Médecine Centre Hospitalo universitaire   (France)

^h UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Alzheimer's disease; caregivers; cohort study; cost; dementia; Europe; informal care; Mini Mental State examination; observational study; resource use

Indexed keywords

CHOLINESTERASE INHIBITOR; MEMANTINE;

ACCOUNTING; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CAREGIVER; COMMUNITY CARE; COST BENEFIT ANALYSIS; DAILY LIFE ACTIVITY; DEMENTIA; DISEASE ASSOCIATION; DISEASE SEVERITY; EUROPE; FEMALE; FRANCE; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESOURCE MANAGEMENT; SENSITIVITY ANALYSIS; SOCIAL CARE; SOCIOECONOMICS; STUDY DESIGN; TIME; UNITED KINGDOM;

EID: 84879618384     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122392     Document Type: Article

References (48)

1. Alzheimer's Disease International (2009) World Alzheimer Report 2009. The Global Prevalence of Dementia, pp. 25-44, ADI, London, http://www.alz.co.uk/ research/worldreport, October 10, 2012, Accessed on October 29, 2012
2. Qiu C, Kivipelto M, von Strauss E (2009) Epidemiology of Alzheimer's disease: Occurrence, determinants and strategies toward intervention. Dialogues Clin Neurosci 11, 111-128
3. Nourhashemi F, Olde Rikkert MG, Burns A, Winblad B, Frisoni GB, Fitten J,VellasB(2010) Follow-up for Alzheimer patients: European Alzheimer disease consortium position paper. J Nutr Health Aging 14, 121-130
4. Wimo A, Prince M Alzheimer's Disease International (2010) World Alzheimer Report 2010. The Global Economic Impact of Dementia. ADI, London, http://www.alz.co.uk/research/ files/WorldAlzheimerReport2010.pdf, Accessed on October 29, 2012
5. Wimo A, Winblad B, Jönsson L (2010) The worldwide societal costs of dementia: Estimates for 2009. Alzheimers Dement 6, 98-103
6. Wimo A, Jönsson L, Gustavsson A, McDaid D, Ersek K, Georges J, Guĺacsi L, Karpati K, Kenigsberg P, Valtonen H (2011) The economic impact of dementia in Europe in 2008 -cost estimates from the Eurocode project. Int J Geriatr Psychiatr 26, 825-832
7. Jönsson L, Wimo A (2009) The cost of dementia in Europe. A review of the evidence and methodological considerations. Pharmacoeconomics 27, 391-403
8. Coduras A, Rabasa I, Frank A, Bermejo-Pareja F, Ĺopez-Pousa S, Ĺopez-Arrieta J-M, Del Llano J, Léon T, Rejas J (2010) Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: The ECO Study. J Alzheimers Dis 19, 601-615
9. Mauskopf J, Racketa J, Sherrill E (2010) Alzheimer's disease: The strength of association of costs with different measures of disease severity. J Nutr Health Aging 14, 655-663
10. Quentin W, Riedel-Heller SG, Luppa M, Rudolph A, König H-H (2010) Cost-of-illness studies of dementia: A systematic review focusing on stage dependency of costs. Acta Psychiatr Scand 121, 243-259
11. Gustavsson A, Cattelin F, Jönsson L (2011) Costs of care in a mild-To-moderate Alzheimer clinical trial sample: Key resources and their determinants. Alzheimers Dement 7, 466-473
12. Gustavsson A, Brinck P, Bergvall N, Kolasa K, Wimo A, Winblad B, Jönsson L (2011) Predictors of costs of care in Alzheimer's disease:Amultinational sample of 1222 patients. Alzheimers Dement 7, 318-327
13. Handels RLH,WolfsCAG, Aalten P,Verhey FRJ, Severens JL (2013) Determinants of care costs of patients with dementia or cognitive impairment. Alzheimer Dis Assoc Disord 27, 30-36
14. Leicht H, Heinrich S, Heider D, Bachmann C, Bickel H, Van den Bussche H, Fuchs A, Luppa M, Maier W, Mösch E, Pentzek M, Rieder-Heller SG, Tebarth F, Werle J, Weyerer S, Wiese B, Zimmermann T, König H-H, for the AgeCoDe study group (2011) Net costs of dementia by disease stage. Acta Psychiatr Scand 124, 384-395
15. Luengo-Fernandez R, Leal J, GrayAM(2011) Cost of dementia in the pre-enlargement countries of the European Union. J Alzheimers Dis 27, 187-196
16. Mesterton J, Wimo A, By A, Langworth S, Winblad B, Jönsson L (2010) Cross sectional observational study on the societal costs of Alzheimer's disease. Curr Alzheimer Res 7, 358-367
17. Reese JP, Hessmann P, Seeberg G, Henkel D, Hirzmann P, Rieke J, Baum E, Dannhoff F, Müller MJ, Jessen F, Geldsetzer M-B, Dodel R (2011) Cost of care of patients with Alzheimer's disease: Clinical predictors in German health care settings. J Alzheimers Dis 27, 723-736
18. Lindholm C, Gustavsson A, Jönsson L,Wimo A (2012) Costs explained by function rather than diagnosis -results from the SNAC Nordanstig elderly cohort in Sweden. Int J Geriatr Psychiatry 28, 454-462
19. Schwarzkopf L, Menn P, Kunz S, Holle R, Lauterberg J,Marx P, Mehlig H,Wunder S, Leidl R, Donath C, Graessel E (2011) Costs of care for dementia patients in community setting: An analysis for mild and moderate disease stage. Value Health 14, 827-835
20. De Meijer C, BrouwerW, Koopmanschap M, Van den Berg B, Van Exel J (2010) The value of informal care -A further investigation of the feasibility of contingent valuation in informal caregivers. Health Economics 19, 755-771
21. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944 (Pubitemid 14076461)
22. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 2, 189-198
23. National Institute of Health and Clinical Excellence (2011) NICE technology appraisal guideline 217. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. http://www.nice.org.uk/ guidance/ TA217. Accessed on November 19, 2012
24. Dementia UK (2007) A report into the prevalence and cost of dementia prepared by the Personal Social Services Research Unit (PSSRU) at the London School of Economics and the Institute of Psychiatry at King's College London, for the Alzheimer's Society. Alzheimer's Society, London, http:// www.alzheimers.org.uk/site/scripts/download info.php?file ID=2, Accessed on October 23, 2012
25. Wimo A, Wetterholm AL, Mastey V, Winblad B (1998) Evaluation of resource utilization and caregiver time in anti-Dementia drug trials a quantitative battery. The Health Economics of Dementia, Wimo A, Jonsson B, Karlsson G, Eds. John Wiley and Sons, London, pp. 465-499
26. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141, 1356-1364
27. GalaskoD, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S, the ADCS (1997) An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 11, S33-S39.
28. Galasko D, Schmitt F, Thomas R, Jin S, Bennett D, Ferris S, for the Alzheimer's disease cooperative study (2005) Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. J Int Neuropsychol Soc 11, 446-453 (Pubitemid 41167182)
29. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Neurology 44, 2306-2314
30. Cummings JL (1997) The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology 48(Suppl 6), 10-16
31. Kind P (1996) The EuroQol instrument: An index of health-related quality of life. In Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edition, Spilker B, Ed. Lippincott-Raven Publishers, Philadelphia, pp. 191-201
32. Szende A, Oppe M, Devlin N, Eds. (2007) EQ-5D value sets: Inventory, comparative review and user guide. Series: Euro-Qol Group Monographs, Vol 2, Springer, the Netherlands
33. The EuroQol, Group (1990) Euro-QoL -A newfacility for the measurement of health-related quality of life. Health Policy 16, 199-208
34. The EuroQol Group (2012) Proxy Paper: EQ-5D-3L, http://www.euroqol.org/ eq-5d-products/eq-5d-3l/proxypaper. html, Accessed on October 30, 2012
35. Karlsson G,Wimo A, Jönsson B,Winblad B (1998) Methodological issues in health economic studies of dementia. In The Health Economics of Dementia, Wimo A, Karlsson G, Jönsson B, Winblad B, Eds. Wiley, London, pp. 161-169
36. Johannesson M, Borgquist L, Jönsson B, Rastam L (1991) The costs of treating hypertension -An analysis of different cut-off points. Health Policy 18, 141-150
37. Coley N, Gardette V, Toulza O (2008) Predictive factors of attrition in a cohort of Alzheimer disease patients. Neuroepidemiology 31, 69-79
38. Nixon R, Wonderling D, Grieve R (2010) Non-parametric methods for cost-effectiveness analysis: The central limit theorem and the bootstrap compared. Health Econ 19, 316-333
39. Schwarzkopf L, Menn P, Leidl R, Wunder S, Mehlig H, Marx P, Graessel E, Holle R (2012) Excess costs of dementia disorders and the role of age and gender -An analysis of German health and long-Term care insurance claims data. BMC Health Services Research 12, 165, http://www.biomedcentral. com/1472-6963/12/ 165, Accessed on October 29, 2012
40. Wimo A, Jönsson L, Zbrozek A (2010) The Resource Utilization in Dementia (RUD) instrument is valid for assessing informal care time in community-Living patients with dementia. J Nutr Health Aging 14, 685-690
41. Gustavsson A, Jönsson L, McShane R, Boada M, Wimo A, Zbrozek AS (2010)Willingness-To-pay for reductions in care need: Estimating the value of informal care in Alzheimer's disease. Int J Geriatr Psychiatry 25, 622-632
42. Gustavsson A, Jönsson L, Rapp T, Reynish E, Ousset PJ, Andrieu S, Cantet C, Winblad B, Vellas B, Wimo A, the ICTUS Study Group (2010) Differences in resource use and costs of dementia care between European countries: Baseline data from the ICTUS study. J Nutr Health Aging 14, 648-654
43. Connolly S, Gillespie P, O'Shea E, Cahill S, PierceM(2012) Estimating the economic and social costs of dementia in Ireland. Dementia. doi: 10.1177-1471301212442453
44. Costa N, Derumeaux H, Rapp T, Garnualt V, Ferlicoq L, Gillette S, Andrieu S, Vellas B, Lamure M, Grand A, Molinier L (2012) Methodological considerations in cost of illness studies on Alzheimer disease. Health Econ Rev 2, 18. doi: 10.1186/2919-1991-2-18
45. Vina J, Lloret A (2010) Why women have more Alzheimer's disease than men: Gender and mitochondrial toxicity of amyloid-beta peptide. J Alzheimers Dis 20(Suppl 2), S527-S553
46. Jönsson L, Eriksdotter Jönhagen M, Kilander L, Soininen H, Hallikainen M, Waldemar G, Nygaard H, Andreasen N, Winblad B,Wimo A (2006) Determinants of costs of care for patients with Alzheimer's disease. Int J Geriatr Psychiatry 21, 449-459
47. Reynish E, Cortes F, Andrieu S, Cantet C, Olde Rikkert M, Melis R, Forelich L, Frisoni GB, Jonsson L, Visser PJ, Ousset PJ, Vellas B, ICTUS Study Group (2007) The ICTUS study: A prospective longitudinal observational study of 1,380 AD patients in Europe. Neuroepidemiology 29, 29-38
48. Froelich L, Andreasen N, Tsolaki M, Foucher A, Kavanagh S, Van Baelen B, Schwalen S (2009) Long-Term treatment of patients with Alzheimer's disease in primary and secondary care: Results from an international survey. Curr Med Res Opin 25, 3059-3068